Abstract: The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).

Abstract: Embodiments of the present invention may track a user's interaction trajectory associated with a problem occurred on a website. According to an embodiment of the present invention, a first symbol of a first definition associated with a first object file is obtained. Then, in response to the first symbol matching a second symbol of a second definition associated with a second object file, the first object file is optimized based on a first segment associated with the first definition in the first object file and an optimization to the second object file is skipped. Next, an executable file is generated based on the optimized first object file and the second object file.

Abstract: Embodiments of the present disclosure include a method for treating Systemic Lupus Erythematosus (SLE) using CD19 CAR T cells. The method includes administering to the human patient a pharmaceutically effective amount of a population of T cells of the human patient that express a chimeric antigen receptor (CAR) that comprises the amino acid sequence of, e.g., SEQ ID NO: 23.

Abstract: Embodiments relate to a modified cell comprising an antigen binding molecule, and the expression and/or function of one or more genes in the modified cell has been enhanced or reduced or eliminated. The one or more genes include CXCR3, SLC1A3, YAP, TIGIT, S1P1, and IL-35. In embodiments, the cell is a T cell, a dendritic cell, a NK cell, or a macrophage cell. In embodiments, the antigen binding molecule comprises a chimeric antigen receptor (CAR) and/or the second antigen binding molecule is a T Cell Receptor (TCR).

Abstract: The present disclosure relates to compositions and methods for enhancing CAR T therapy through uses of co-stimulation. Some embodiments relate to an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR) and an agent associated with a co-stimulatory molecule, the CAR comprising an intracellular domain of a costimulatory molecule.

Abstract: Disclosed are a bitstream alignment and synchronous processing method, transmitting terminal, receiving terminal and communication system. The method includes: configuring, when multiple bitstreams are required to be aligned, by a transmitting terminal, alignment auxiliary information in the multiple bitstreams so as to store the same or transmit the same to a receiving terminal; and acquiring, by the receiving terminal, the multiple bitstreams, and synchronizing each of the bitstreams of a different standard according to the alignment auxiliary information carried in each of the bitstreams.

Abstract: Disclosed are an image encoding and decoding method, image processing device, and computer storage medium, comprising: entropy-encoding a plurality of replication parameters of a current encoding block according to their order after adjustment, to generate a video code stream comprising information of the plurality of replication parameters; said plurality of replication parameters comprising one or more types of replication parameter components. Parsing the video code stream, comprising the information of the plurality of replication parameters, of a decoding block; entropy-decoding said plurality of replication parameters to obtain binary code of said plurality of replication parameters; adjusting said binary code to obtain the values of said plurality of replication parameters; said plurality of replication parameters comprising one or more types of replication parameter components.

Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.

Abstract: A method and device for processing and accessing image are provided. The image processing method includes: one or more protected areas are determined in an original picture to be processed, image data of the one or more protected areas are protected by adding access rights, one or more independent sub-image data corresponding to the one or more protected areas are obtained, and then the one or more protected areas in the original picture are shielded to obtain main image data, the images in the protected areas being invisible in the shielded original picture; and the one or more obtained independent sub-image data and the obtained main image data are associatively stored.

Abstract: Embodiments herein relate to humanized CD19 antibodies and disease treatment using the antibodies. For example, a subject having a CD19 positive tumor may be administered a therapeutically effective amount of the humanized antibody.

Abstract: Embodiments herein relate to humanized CD19 antibodies and disease treatment using the antibodies. For example, a subject having a CD19 positive tumor may be administered a therapeutically effective amount of the humanized antibody.

Abstract: Provided are a media information processing method, apparatus and system. The method comprises: generating media indication information according to a media state and/or a media state change, wherein the media indication information at least comprises one of the following: a media identifier, a media state type, a media state change type, a media state description, and a media state change description; and sending or storing the media indication information. By means of the present disclosure, the problem in the relevant art that the covered content in media information is incomplete during a media interaction is solved, thereby achieving the effect of improving the media information integrity and expandability.

Abstract: The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).

Abstract: Provided are picture encoding and decoding methods and apparatuses, and a picture encoding and decoding system. The picture encoding method includes: determining an adjustment factor according to pixel sampling values of a video picture; converting the video picture according to the adjustment factor, and encoding the converted video picture; and writing the adjustment factor into a bitstream obtained by encoding the converted video picture.

Abstract: Disclosed are an encoding processing method and device, a decoding processing method and device, an encoder and a decoder. The encoding processing method includes: determining a filtering process to be applied to a pixel in a prediction reference block for an encoding block; filtering the pixel in the prediction reference block according to the filtering process; constructing a pixel prediction value for the encoding block according to a filtered pixel sampling value in the prediction reference block; and encoding the encoding block according to the pixel prediction value.

Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.

Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using modified T cells in which TRAC genes are inactivated using a Zinc-finger nuclease (ZFN). The ZFN may include a first zinc finger protein (ZFP) that binds a first target site in a T-cell receptor alpha constant (TRAC) gene and a second ZFP that binds a second target site in the TRAC gene.

Abstract: Provided is an encoding and decoding method and device for data compression. The encoding method includes: adaptively selecting a constrained string mode from a plurality of preset constrained string modes; and performing, according to the selected constrained string mode, string-matching encoding on a coding block to obtain information of a constrained string encoded in the selected constrained string mode and to obtain a bitstream of a syntax element of the constrained string encoded in the selected constrained string mode.

Abstract: The present disclosure provides picture encoding and decoding methods, picture encoding and decoding devices as well as a decoder and an encoder. The picture decoding method includes: parsing a video bitstream to obtain candidate reshaping parameters from a picture-layer and/or slice-layer data unit of the video bitstream, and determining a reshaping parameter used for reshaping a reconstructed picture according to the obtained candidate reshaping parameters; and reshaping the reconstructed picture by using the reshaping parameter. The reconstructed picture is a picture obtained by decoding the video bitstream before performing the reshaping.

Abstract: Embodiments described herein relate to compositions including genetically modified CAR cells and uses thereof for treating cancer. Some embodiments of the present disclosure relate to compositions and methods for T cell response enhancement and/or CAR cell preparation. For example, a method may include obtaining cells comprising a CAR and culturing the cells in the presence of an agent that is recognized by the extracellular domain of the CAR.